[1]OrganicProcessResearchandDevelopment,2014,vol.18,p.546-551
Title: Recent advances in pharmacotherapy for hypertriglyceridemia.
Journal: Progress in lipid research 20141001
Title: Future of cholesteryl ester transfer protein inhibitors.
Journal: Annual review of medicine 20140101
Title: Rationale for cholesteryl ester transfer protein inhibition.
Journal: Current opinion in lipidology 20120801
Title: Evacetrapib.
Journal: Current cardiology reports 20120601
Title: Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20120501
Title: New focus on raising HDL 'good' cholesterol. But the value of this is not entirely clear.
Journal: DukeMedicine healthnews 20120201
Title: Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Journal: Drug design, development and therapy 20120101
Title: [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Journal: MMW Fortschritte der Medizin 20111208
Title: Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Journal: Journal of lipid research 20111201
Title: Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Journal: JAMA 20111116
Title: High-density lipoprotein cholesterol as the Holy Grail.
Journal: JAMA 20111116
Title: Cao G, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52(12):2169-76.
